Hikal Limited has reported its financial results for the first quarter of Fiscal Year 2027 (Q1 FY27), ending June 30, 2026. The company announced a revenue of ₹403 crore and an EBITDA of ₹37 crore, with an EBITDA margin of 9.2%. The company also provided guidance for the full year, expecting revenue growth of 14-16% and EBITDA growth of 25-30%.
Hikal Limited Q1 FY27 Financial Highlights
Hikal Limited has announced its financial performance for the first quarter of Fiscal Year 2027 (Q1 FY27), which concluded on June 30, 2026. The company reported a revenue of ₹403 crore and an Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) of ₹37 crore, resulting in an EBITDA margin of 9.2%. The Profit After Tax (PAT) for the quarter was (-) ₹7 crore.
Segment Performance and Outlook
The Pharmaceutical business reported revenue of ₹233 crore with an EBIT of ₹8 crore and an EBIT margin of 3.2%. The Crop Protection business posted a revenue of ₹170 crore with an EBIT of (-) ₹6 crore. The Animal Health business demonstrated resilience, supported by improving customer demand and portfolio expansion.
Looking ahead, Hikal expects the momentum to build in the second half of FY27. The company has provided full-year guidance, anticipating revenue growth in the range of 14% to 16% and EBITDA growth of 25% to 30%. This growth is expected to be driven by the Pharma and Animal Health segments, with the Personal Care business also contributing as it scales up.
Strategic Initiatives and Future Growth
Hikal continues to focus on enhancing its R&D capabilities and expanding its CDMO partnerships. The company is strategically investing in new growth platforms, including Animal Health and Personal Care, with the aim of significant revenue contribution from these segments in the coming years. The company is also progressing with its U.S. FDA remediation program, expecting a re-inspection towards the end of the financial year.
Source: BSE
